Omeros downgraded by BofA Securities with a new price target
$OMER
Biotechnology: Pharmaceutical Preparations
Health Care
BofA Securities downgraded Omeros from Neutral to Underperform and set a new price target of $3.00 from $8.00 previously
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/10/2025 | $9.00 | Buy | H.C. Wainwright |
| 12/23/2024 | $36.00 | Buy | D. Boral Capital |
| 11/14/2024 | $9.00 | Buy | Rodman & Renshaw |
| 12/8/2022 | $12.00 → $2.00 | Buy → Neutral | UBS |
| 11/8/2022 | $8.00 → $3.00 | Neutral → Underperform | BofA Securities |
| 6/8/2022 | $12.00 → $4.00 | Buy → Neutral | BofA Securities |
| 10/19/2021 | $19.00 → $12.00 | Buy | HC Wainwright & Co. |
| 10/8/2021 | Neutral → Underweight | JP Morgan |
H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
D. Boral Capital initiated coverage of Omeros with a rating of Buy and set a new price target of $36.00
Rodman & Renshaw initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
10-Q - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
8-K - OMEROS CORP (0001285819) (Filer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
4 - OMEROS CORP (0001285819) (Issuer)
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six months ended June 30, 2025, our net loss was $58.9 million, or $1.01 per share, compared to a net loss of $93.2 million, or $1.60 per share in the corresponding prior year period. The reduction in net loss from the prior year quarter was primarily related to narsoplimab drug substance manufacturing
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have
Omeros Corporation (NASDAQ:OMER) ("Omeros" or the "Company") announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 5,365,853 shares of its common stock at a price of $4.10 per share, which represents a premium of approximately 14% to the closing price of the Company's common stock on the date of the securities purchase agreement. The gross proceeds to the Company from the registered direct offering are estimated to be approximately $22 million, before dedu
Omeros Corporation (NASDAQ:OMER) today announced that Andreas Grauer, M.D., has been named Omeros' chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical affairs, safety, and biometrics. A highly tenured physician, scientist and pharmaceutical leader, Dr. Grauer brings to Omeros over 20 years of industry experience across a broad range of therapeutic areas including inflammation, nephrology, oncology, neurology, endocrinology, and metabolism. "We are very pleased to welcome Andreas to Omeros' leadership team," said Gregory A. Demopulos, M.D., chairman and ch
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G/A - OMEROS CORP (0001285819) (Subject)
SC 13G - OMEROS CORP (0001285819) (Subject)
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have
– Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER) today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2025, which include: Net loss for the first quarter of 2025 was $33.5 million, or $0.58 per share, compared to a net loss of $37.2 million, or $0.63 per share for the first quarter of 2024. At March 31, 2025, we had $52.4 million of cash and short-term investments available for operations and debt servicing, a decrease of $37.7 million from December 31, 2024. In March 2025, we resubmitted to the U.S. Food and Drug Administration ("FDA") our Biologics License Application ("BLA") seeking regulatory
Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its financial results for the quarter ended March 31, 2025, on Thursday, May 15, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conference call, go to Omeros' website at https://investor.omeros.com/upcoming-events. To access the live conference call via phone, participants must register at this link to receive a unique PIN. Once registered, you will have two o